JP2019218375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019218375A5 JP2019218375A5 JP2019150947A JP2019150947A JP2019218375A5 JP 2019218375 A5 JP2019218375 A5 JP 2019218375A5 JP 2019150947 A JP2019150947 A JP 2019150947A JP 2019150947 A JP2019150947 A JP 2019150947A JP 2019218375 A5 JP2019218375 A5 JP 2019218375A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- disease
- compound according
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 3
- 125000001118 alkylidene group Chemical group 0.000 claims 3
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 claims 2
- WQMQRNCPZFUGID-UHFFFAOYSA-N 2-azaniumyladamantane-2-carboxylate Chemical compound C1C(C2)CC3CC1C(C(O)=O)(N)C2C3 WQMQRNCPZFUGID-UHFFFAOYSA-N 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- FHJXLSAWYORMMX-UHFFFAOYSA-N 9-aminobicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound C1CCC2CCCC1C2(N)C(O)=O FHJXLSAWYORMMX-UHFFFAOYSA-N 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000591385 Homo sapiens Neurotensin receptor type 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000017922 Neurotensin receptor Human genes 0.000 claims 1
- 108060003370 Neurotensin receptor Proteins 0.000 claims 1
- 102100033986 Neurotensin receptor type 1 Human genes 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12008208.6 | 2012-12-07 | ||
| EP12008208.6A EP2740726A1 (en) | 2012-12-07 | 2012-12-07 | Neurotensin receptor ligands |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545697A Division JP6576828B2 (ja) | 2012-12-07 | 2013-12-06 | ニューロテンシン受容体リガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019218375A JP2019218375A (ja) | 2019-12-26 |
| JP2019218375A5 true JP2019218375A5 (https=) | 2020-05-07 |
| JP7042776B2 JP7042776B2 (ja) | 2022-03-28 |
Family
ID=47355771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545697A Active JP6576828B2 (ja) | 2012-12-07 | 2013-12-06 | ニューロテンシン受容体リガンド |
| JP2019150947A Active JP7042776B2 (ja) | 2012-12-07 | 2019-08-21 | ニューロテンシン受容体リガンド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545697A Active JP6576828B2 (ja) | 2012-12-07 | 2013-12-06 | ニューロテンシン受容体リガンド |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10961199B2 (https=) |
| EP (3) | EP2740726A1 (https=) |
| JP (2) | JP6576828B2 (https=) |
| KR (1) | KR102290803B1 (https=) |
| CN (2) | CN109320502B (https=) |
| AU (1) | AU2013354422B2 (https=) |
| BR (1) | BR112015012530B1 (https=) |
| CA (1) | CA2893605C (https=) |
| DK (2) | DK3712131T3 (https=) |
| ES (2) | ES2941629T3 (https=) |
| FI (1) | FI3712131T3 (https=) |
| HU (2) | HUE050388T2 (https=) |
| IL (1) | IL239080B (https=) |
| MX (1) | MX370354B (https=) |
| PL (2) | PL2928870T3 (https=) |
| PT (2) | PT2928870T (https=) |
| RU (1) | RU2671970C2 (https=) |
| SG (2) | SG11201503880YA (https=) |
| WO (1) | WO2014086499A1 (https=) |
| ZA (1) | ZA201503446B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2954933A1 (en) * | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| EP2954934A1 (en) * | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand and use thereof |
| RU2743781C2 (ru) | 2014-06-10 | 2021-02-25 | 3Б Фармасьютикалз Гмбх | Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение |
| SI3380495T1 (sl) | 2015-11-24 | 2022-01-31 | Transfert Plus, S.E.C. | Peptidne spojine in peptidni konjugati za zdravljenje raka z receptorsko posredovano kemoterapijo |
| EP3279197A1 (en) | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
| EP4649966A3 (en) | 2016-12-01 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| EA201991673A1 (ru) | 2017-02-10 | 2020-01-17 | Регенерон Фармасьютикалз, Инк. | Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации |
| SG11202000073XA (en) | 2017-07-24 | 2020-02-27 | Regeneron Pharma | Anti-cd8 antibodies and uses thereof |
| FI3997103T3 (fi) | 2019-07-08 | 2025-02-03 | 3B Pharmaceuticals Gmbh | Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö |
| AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
| CN111875667B (zh) * | 2020-07-16 | 2021-12-21 | 南方科技大学 | 有机金属螯合物及其制备方法与应用、探针 |
| JP7773990B2 (ja) * | 2020-10-22 | 2025-11-20 | 日本メジフィジックス株式会社 | 放射性ジルコニウム錯体の製造方法 |
| EP4326344A4 (en) * | 2021-04-23 | 2025-05-07 | Fusion Pharmaceuticals Inc. | Methods for treatment of cancers |
| AU2022273867A1 (en) * | 2021-05-13 | 2023-11-23 | The General Hospital Corporation | Molecular probes for in vivo detection of aldehydes |
| EP4355317A4 (en) * | 2021-06-16 | 2025-04-30 | Fusion Pharmaceuticals Inc. | COMBINATION WITH A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX |
| EP4355377A4 (en) * | 2021-06-16 | 2025-05-07 | Fusion Pharmaceuticals Inc. | COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL |
| WO2022261770A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and folfirinox |
| IL314533A (en) * | 2022-01-28 | 2024-09-01 | Fusion Pharmaceuticals Inc | Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy |
| EP4479040A1 (en) * | 2022-02-18 | 2024-12-25 | Full-Life Technologies HK Limited | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
| AU2023264077A1 (en) * | 2022-05-03 | 2024-11-14 | The University Of North Carolina At Chapel Hill | Development of ntsr targeted agents for imaging and therapy applications |
| US12091454B2 (en) | 2022-12-28 | 2024-09-17 | Development Center For Biotechnology | Humanized anti-human neurotensin receptor 1 antibodies and their uses |
| US20250213735A1 (en) * | 2023-12-28 | 2025-07-03 | Radionetics Oncology, Inc. | Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof |
| WO2025146126A1 (en) * | 2024-01-04 | 2025-07-10 | Full-Life Technologies Hk Limited | Preparation method of compounds targeting neurotensin receptor |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110321A (en) | 1976-07-12 | 1978-08-29 | Folkers Karl | Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity |
| US4425269A (en) | 1982-06-07 | 1984-01-10 | Merck & Co., Inc. | Metabolically protected analogs of neurotensin |
| US4439359A (en) | 1982-07-02 | 1984-03-27 | Merck & Co., Inc. | Cyclic octapeptide analogs of neurotensin |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2086453A1 (en) | 1992-12-30 | 1994-07-01 | Mcgill University | Marker for neurotensin receptor |
| US5407916A (en) | 1993-02-16 | 1995-04-18 | Warner-Lambert Company | Neurotensin mimetics as central nervous system agents |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| WO1995022341A1 (en) | 1994-02-18 | 1995-08-24 | Mallinckrodt Medical, Inc. | Labelled peptide compounds |
| US6054557A (en) | 1995-04-04 | 2000-04-25 | Advanced Bioconcept (1994) Ltd. | Fluorescent peptides |
| EP0820466A2 (en) | 1995-04-04 | 1998-01-28 | Advanced Bioconcept Inc. | Fluorescent peptides |
| FR2732967B1 (fr) * | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| AU6352296A (en) | 1995-07-20 | 1997-02-18 | Advanced Bioconcept, Inc. | Cell sorting with fluorescent peptides |
| AU728712C (en) | 1997-02-03 | 2001-07-19 | Mallinckrodt, Inc. | Method for the detection and localization of malignant human tumours |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| AU3485999A (en) | 1998-04-10 | 1999-11-01 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| EP1194444A2 (en) | 1999-06-24 | 2002-04-10 | BioSynthema Inc. | Labeled neurotensin derivatives with improved resistance to enzymatic degradation |
| US20050112065A1 (en) * | 2003-07-09 | 2005-05-26 | Drummond Daryl C. | Remote detection of substance delivery to cells |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| EP2114461A2 (en) * | 2007-01-19 | 2009-11-11 | Mallinckrodt Inc. | Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| EP2334642B1 (en) * | 2008-09-16 | 2014-01-01 | The Regents Of The University Of California | Simplified one-pot synthesis of [18f]sfb for radiolabeling |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| WO2010079158A1 (en) * | 2009-01-07 | 2010-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment, the prognostic assessment and the detection of breast cancer |
| WO2011006985A1 (en) | 2009-07-16 | 2011-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors |
| WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
-
2012
- 2012-12-07 EP EP12008208.6A patent/EP2740726A1/en not_active Withdrawn
-
2013
- 2013-12-06 ES ES20166422T patent/ES2941629T3/es active Active
- 2013-12-06 HU HUE13814827A patent/HUE050388T2/hu unknown
- 2013-12-06 SG SG11201503880YA patent/SG11201503880YA/en unknown
- 2013-12-06 MX MX2015007193A patent/MX370354B/es active IP Right Grant
- 2013-12-06 FI FIEP20166422.4T patent/FI3712131T3/fi active
- 2013-12-06 CA CA2893605A patent/CA2893605C/en active Active
- 2013-12-06 HU HUE20166422A patent/HUE061839T2/hu unknown
- 2013-12-06 JP JP2015545697A patent/JP6576828B2/ja active Active
- 2013-12-06 KR KR1020157018171A patent/KR102290803B1/ko active Active
- 2013-12-06 US US14/650,437 patent/US10961199B2/en active Active
- 2013-12-06 PT PT138148275T patent/PT2928870T/pt unknown
- 2013-12-06 EP EP13814827.5A patent/EP2928870B1/en active Active
- 2013-12-06 DK DK20166422.4T patent/DK3712131T3/da active
- 2013-12-06 RU RU2015127086A patent/RU2671970C2/ru active
- 2013-12-06 AU AU2013354422A patent/AU2013354422B2/en active Active
- 2013-12-06 PT PT201664224T patent/PT3712131T/pt unknown
- 2013-12-06 PL PL13814827T patent/PL2928870T3/pl unknown
- 2013-12-06 BR BR112015012530-1A patent/BR112015012530B1/pt active IP Right Grant
- 2013-12-06 DK DK13814827.5T patent/DK2928870T3/da active
- 2013-12-06 PL PL20166422.4T patent/PL3712131T3/pl unknown
- 2013-12-06 ES ES13814827T patent/ES2795923T3/es active Active
- 2013-12-06 CN CN201811305966.0A patent/CN109320502B/zh active Active
- 2013-12-06 CN CN201380063364.8A patent/CN104837819B9/zh active Active
- 2013-12-06 EP EP20166422.4A patent/EP3712131B1/en active Active
- 2013-12-06 SG SG10201704564QA patent/SG10201704564QA/en unknown
- 2013-12-06 WO PCT/EP2013/003700 patent/WO2014086499A1/en not_active Ceased
-
2015
- 2015-05-18 ZA ZA2015/03446A patent/ZA201503446B/en unknown
- 2015-05-28 IL IL239080A patent/IL239080B/en active IP Right Grant
-
2019
- 2019-08-21 JP JP2019150947A patent/JP7042776B2/ja active Active
-
2020
- 2020-12-04 US US17/112,258 patent/US20210087149A1/en not_active Abandoned
-
2025
- 2025-05-29 US US19/222,493 patent/US20260078095A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019218375A5 (https=) | ||
| CN103251579B (zh) | 取代的n-酰基苯胺及其使用方法 | |
| KR101542812B1 (ko) | 당뇨병을 치료하기 위한 선택적인 안드로겐 수용체 모듈레이터 | |
| JP2022536728A5 (https=) | ||
| RU2015127086A (ru) | Лиганды рецептора нейротензина | |
| JP2010504079A5 (https=) | ||
| JP2004505105A5 (https=) | ||
| IL255261B2 (en) | A combination of an m-tor inhibitor and rad19010 for use in a method of inhibiting tumor growth or producing tumor regression in a subject having a deug-resistant andqor mutant estrogen receptor | |
| CN103619330A (zh) | 用于治疗糖尿病的选择性雄激素受体调节剂 | |
| JP2021525768A (ja) | Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法 | |
| RU2011108026A (ru) | Комбинированная терапия туберкулеза | |
| JP2006517939A5 (https=) | ||
| USRE50319E1 (en) | Compounds and methods for treating cancer | |
| JP2004518674A5 (https=) | ||
| JP2010521516A5 (https=) | ||
| RU2019114079A (ru) | Лечение er+ рака молочной железы лазофоксифеном | |
| JP2017530163A5 (https=) | ||
| US9889110B2 (en) | Selective androgen receptor modulator for treating hormone-related conditions | |
| JP2022539185A5 (https=) | ||
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| KR20160067225A (ko) | 암 환자에서 근육 소모를 치료하는 선택적 안드로겐 수용체 조절물질 및 화학치료제 | |
| JP2013507345A5 (https=) | ||
| JP2008501632A5 (https=) | ||
| JP2006517195A5 (https=) | ||
| CN114174297B (zh) | 雌激素受体调节化合物 |